Last reviewed · How we verify
CD10367 1% Solution - Non-desquamated zone
CD10367 is a topical solution designed to treat non-desquamated (non-scaling) skin lesions, likely through anti-inflammatory or keratolytic activity.
CD10367 is a topical solution designed to treat non-desquamated (non-scaling) skin lesions, likely through anti-inflammatory or keratolytic activity. Used for Non-desquamated skin lesions (Phase 2).
At a glance
| Generic name | CD10367 1% Solution - Non-desquamated zone |
|---|---|
| Sponsor | Galderma R&D |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 2 |
Mechanism of action
CD10367 1% solution is a dermatological agent in Phase 2 development by Galderma R&D. The specific mechanism of action is not publicly disclosed, but given its topical formulation and indication for non-desquamated zones, it likely works through local anti-inflammatory, antimicrobial, or tissue-remodeling pathways. The designation of 'non-desquamated zone' suggests it targets lesions without significant scaling.
Approved indications
- Non-desquamated skin lesions (Phase 2)
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CD10367 1% Solution - Non-desquamated zone CI brief — competitive landscape report
- CD10367 1% Solution - Non-desquamated zone updates RSS · CI watch RSS
- Galderma R&D portfolio CI